跳至主要内容
临床试验/NCT06116903
NCT06116903招募中不适用

Clinical Relevance of Detecting Molecular Abnormalities in Glial Tumor Exosomes

University Hospital, Limoges2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2024年4月11日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
60
试验地点
2
主要终点
Analyse Next-generation sequencing (NGS)

研究概览

简要总结

The purpose of this pilot study is that exosomes constitute a more interesting support for analyzes allowing a broader screening of molecular alterations to be carried out with more reliable, more sensitive and more efficient results than the reference Foundation One Liquid CDx test.

详细描述

Gliomas are the most common primary brain tumors in adults. The heterogeneity of tumors, the lack of reliable criteria for identifying different subtypes make their histopathological diagnosis and their management complex. The molecular profiling from circulating exosomes is one of the most promising approaches to better characterize gliomas.

We will demonstrate the superiority of detection by NGS of molecular abnormalities present in exosomes from glioblastomas, compared to detection by the Foundation One Liquid CDx test on ctDNA.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject of both sexes at least 18 years of age with glioblastoma.
  • Patient for whom an FMI test is indicated, progressing after a 1st line following the chemotherapy and radiotherapy protocol (STUPP protocol)
  • Patient affiliated to French social security

排除标准

  • Patient included in another research protocol using an experimental molecule.
  • Any medical or psychiatric condition which, in the Investigator's opinion, would preclude the patient from adhering to the protocol or completing the study per protocol
  • Patient under legal protection, guardianship or curatorship
  • Patient with active malignancy or a previous malignancy within the past 5 years; except for patient with resected Basocarcinoma and resected carcinoma in-situ of the cervix.

结局指标

主要结局

Analyse Next-generation sequencing (NGS)

时间窗: 3 months

Higher proportion of contributory samples identified by NGS analysis (via exosomes) compared to that of FMI (Foundation Medicine International) test (at inclusion)

次要结局

  • Molecular alterations(3 months)
  • Expression of biomarkers(3 months)
  • carbon footprint(3 months)

研究者

发起方
University Hospital, Limoges
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Clinical Relevance of Detecting Molecular... | 临床试验